Wave Life Sciences is trading at $3.55, down 5.33%, during the October 6, 2026 session amid biotech-sector weakness.
- The supplied sector context says XBI is down 2.50%; a live market listing also showed XBI lower.
- No clear company-specific catalyst surfaced. Wave’s FDA-pathway update was reported earlier, not as new news today.
- Major U.S. indexes are higher, so broad-market weakness does not appear to explain the move.